The effects on clotting tests and platelet function of six months' continuous administration of the 19-norsteroid, progestogen-only contraceptive, norethisterone, have been studied in four groups of women. In a group of women who have not previously taken oral contraceptive no acceleration of clotting or platelet factors was found, but in contrast a tendency to reduced coagulability was observed. Women who had previously been taking combined oestrogen-progestogen preparations showed reduced clotting and platelet parameters when norethisterone was substituted. No changes in clotting or platelets were found in women who changed from 17-acetoxysteroid progestogen chloramadinone acetate or in a group of women started postpartum.
Introduction
Oestrogen-progestogen oral contraceptives produce acceleration of blood clotting (Thomson and Poller, 1965; Poller et al., 1968) and increased platelet aggregation (Poller et al., 1969) . Changes in clotting have not been detected, however, with a 17-acetoxysteroid progestogen, chlormadinone acetate, when used as a progestogen-only oral contraceptive. Platelet changes were delayed and less severe than with combined preparations (Poller et al., 1971a) .
Since 1969, when chlormadinone acetate was withdrawn from sale for reasons unconnected with thrombosis, only combined preparations have been marketed. Recently the 19-norsteroid progestogen, norethisterone, became available for clinical trial. There is evidence that 19-norsteroids may be broken down into oestrogen in the body (Brown and Blair, 1960) and thus might resemble combined preparations in producing undesirable effects on blood clotting.
A study has therefore been conducted on the effects of the continuous daily administration of 0-35 mg norethisterone in a group of 63 women volunteers followed for a period of six monthly cycles.
Subjects and Method
Laboratory studies were performed before starting and at intervals of one, two, three, and six months. (Burslem et al., 1972) . The study group were as follows.
Group 1.-Sixteen women who were taking an oral contraceptive for the first time.
Group 2.-Twenty-eight women who had been taking combined oestrogen-progestogen oral contraceptives for an average of 33 months before inclusion in this study. Two women had intervals of up to two months before starting norethisterone, the remainder changed at the end of their current cycle of combined oral contraception.
Group 3.-Thirteen women who had previously been taking the progestogen-only oral contraceptive chlormadinone acetate for at least two years.
Group 4.-Six women who were between the second and fifth month postpartum at the time of the base line studies.
The following tests were performed at each visit by using the techniques described previously (Poller et al., 1971b) : prothrombin time, kaolin-activated cephalin time, factors VII and X assays, thrombelastography (reaction time, thrombin time, and maximum amplitude values), platelet aggregation time (Chandler's tube technique), fibrinogen assay, and haemoglobin and platelet count. The method for factor VII assay was modified from previous reports by the use of congenital factor-VII deficient substrate plasma obtained from beagle dogs instead of coumarin factor-VII deficient plasma (Poller et al., 1971c) . The platelet adhesiveness test, using the technique of Hirsh and McBride (1965) , was performed in 43% of the 265 investigations. The limiting factor was the extra volume of blood required from the women volunteers. Fibrin/fibrinogen breakdown products were measured by two different techniques: the haemagglutination inhibition assay (Merskey et al., 1969) using human group 0 cells, and the staphylococcal clumping test (Leavelle et al., 1971) . Fibrin/fibrinogen breakdown products were measured before starting, and repeated at the three-month and six-month stages. Antithrombin III measurements (Abildgaard et al., 1970) were performed before the start of norethisterone and again after six months.
Results were analysed against the base line readings of the individual group by using the paired t test in all four series.
Results
The women attended on 265 occasions out of a possible maximum of 315 visits. and cephalin times and platelet aggregation times became significantly prolonged between one and three months. Fibrinogen levels became lower than when on combined preparations at one to two months, and a tendency to reduced coagulability was also seen in the thrombelastogram. There was no significant change in fibrin/fibrinogen breakdown products, antithrombin III levels, haemoglobin levels, and platelet counts.
Group 3.-The 13 women who changed from progestogenonly oral contraception with the 17-acetoxysteroid preparation chlormadinone acetate to the 19-norsteroid norethisterone showed no change in clotting or platelet tests or other criteria over the first six months (Table III) .
Group 4.-The postpartum group who were started on norethisterone were analysed separately because of possible postpartum hypercoagulability. There was no evidence of clotting or platelet changes in these six women (Table IV) Blair, 1960). It is now well established that it is the oestrogens wbich appear to be responsible for the adverse effects on clotting and platelet function (Poller et al., 1971a (Poller et al., , 1971b and for the thrombotic tendency (Inman et al., 1970) . The 19-norsteroid nmight in theory therefore have produced similar changes to oestrogen-containing oral contraceptives. The lack of adverse effects on blood clotting with norethisterone is in contrast to our previous findings with all types of conventional combined oral contraceptives where significant rises of factors VII and X as weJl as other undesirable clotting changes occurred within the first three months of administration. In addition, we have found accelerated cephalin times and Chandler's tube platelet aggregation times with combined preparations. A number of authors have found a tendency to increased platelet adhesion (Ygge et al., 1969) with combined preparations. Von Kaulla and von Kaulla (1970) showed a fall in antithrombin III levels with conventional oral contraception. Several authors have also reported rises in fibrinogen levels with oestrogen-progestogen administration (Nilsson and Kullendar, 1967) . The lack of such changes with six months' norethisterone administration is reassuring.
In a previous long-term follow-up of a group taking chlormadinone acetate no change in clotting tests was recorded but acceleration of the Chandler's tube platelet aggregation test was recorded after two years, although this was significantly less then a long-term group on combined ostrogen-progestogen preparations. Longer follow-up will therefore be required to be certain that delayed or cumulative effects do not occur at a later stage of the present study of norethisterone administration.
The absence of adverse effects on clotting and platelets in the group of women not previously having taken oral contraceptives was also supported by the absence of changes in women who changed to norethisterone from chlormadinone acetate and the small group of postpartum patients. None of the patients in this trial suffered from thrombosis but this was unlikely in view of the small size of the groups tested. The absence of clotting and platelet changes is not proof that oral contraception with 19-norsteroid progestogens will be devoid of thrombotic complications, butthe evidence that these undesirable sideeffects on clotting have been avoided raises the possibility of a reduction in thromboembolic risk when they are used instead of combined preparations. (Evensen, 1942; Cameron et al., 1969; Holdsworth et al., 1969; Perreau et al., 1969) . Less attention has been paid to the question of carbohydrate metabolism in the preoperative ulcer patient. Early studies yielded conflicting results, probably because the techniques of the glucose tolerance tests were not standardized and the methods used for estimating blood glucose concentrations were relatively crude. Furthermore, changes in plasma insulin levels could only be inferred from the observed variations in blood glucose concentration.
The importance of the gastrointestinal hormones in modifying the insulin response to ingested carbohydrate is established (McIntyre et al., 1964 (McIntyre et al., , 1965 . The altered gastrointestinal physiology accompanying chronic peptic ulcer disease might be reflected in an abnormal pattern of carbohydrate metabolism. We have used an oral glucose tolerance test with measurement of blood glucose and plasma insujlin concentrations to investigate a group of patients with chronic duodenal ulcer in an attempt to define any such abnormality.
Patients and Methods
Fifteen patients with a lengthy history of dyspepsia, in whom a radiological diagnosis of chronic duodenal ulcer had been
